• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用药代动力学/药效学建模和模拟进行回顾性分析可提高抗疟药物开发中志愿者感染研究设计的效率。

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development.

机构信息

Cognigen Corporation, a SimulationsPlus Company, Buffalo, New York, USA.

Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York, USA.

出版信息

Clin Transl Sci. 2021 Mar;14(2):712-719. doi: 10.1111/cts.12934. Epub 2020 Dec 16.

DOI:10.1111/cts.12934
PMID:33326705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7993277/
Abstract

Volunteer infection studies using the induced blood stage malaria (IBSM) model have been shown to facilitate antimalarial drug development. Such studies have traditionally been undertaken in single-dose cohorts, as many as necessary to obtain the dose-response relationship. To enhance ethical and logistic aspects of such studies, and to reduce the number of cohorts needed to establish the dose-response relationship, we undertook a retrospective in silico analysis of previously accrued data to improve study design. A pharmacokinetic (PK)/pharmacodynamic (PD) model was developed from initial fictive-cohort data for OZ439 (mixing the data of the three single-dose cohorts as: n = 2 on 100 mg, 2 on 200 mg, and 4 on 500 mg). A three-compartment model described OZ439 PKs. Net growth of parasites was modeled using a Gompertz function and drug-induced parasite death using a Hill function. Parameter estimates for the PK and PD models were comparable for the multidose single-cohort vs. the pooled analysis of all cohorts. Simulations based on the multidose single-cohort design described the complete data from the original IBSM study. The novel design allows for the ascertainment of the PK/PD relationship early in the study, providing a basis for rational dose selection for subsequent cohorts and studies.

摘要

志愿者感染研究使用诱导的血期疟疾(IBSM)模型已被证明有助于抗疟药物的开发。此类研究传统上采用单剂量队列进行,需要进行尽可能多的剂量反应关系研究。为了增强此类研究的伦理和逻辑方面,并减少建立剂量反应关系所需的队列数量,我们对以前积累的数据进行了回顾性的计算机分析,以改进研究设计。从初始虚拟队列数据中开发了 OZ439 的药代动力学(PK)/药效动力学(PD)模型(将三个单剂量队列的数据混合在一起:n = 100mg 上的 2 人,200mg 上的 2 人,和 500mg 上的 4 人)。三腔室模型描述了 OZ439 的 PK。寄生虫的净生长用 Gompertz 函数建模,药物诱导的寄生虫死亡用 Hill 函数建模。PK 和 PD 模型的参数估计值在多剂量单队列与所有队列的汇总分析之间具有可比性。基于多剂量单队列设计的模拟描述了原始 IBSM 研究的完整数据。这种新设计允许在研究早期确定 PK/PD 关系,为后续队列和研究提供合理的剂量选择基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74a4/7993277/4e46dc074cf2/CTS-14-712-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74a4/7993277/671551dab85a/CTS-14-712-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74a4/7993277/3a912bea2b2c/CTS-14-712-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74a4/7993277/4e46dc074cf2/CTS-14-712-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74a4/7993277/671551dab85a/CTS-14-712-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74a4/7993277/3a912bea2b2c/CTS-14-712-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74a4/7993277/4e46dc074cf2/CTS-14-712-g003.jpg

相似文献

1
Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development.利用药代动力学/药效学建模和模拟进行回顾性分析可提高抗疟药物开发中志愿者感染研究设计的效率。
Clin Transl Sci. 2021 Mar;14(2):712-719. doi: 10.1111/cts.12934. Epub 2020 Dec 16.
2
Evaluation of a Bayesian hierarchical pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs.评估一种贝叶斯分层药代动力学-药效学模型,用于预测新型抗疟药物 2 期研究中的寄生虫学结局。
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0086324. doi: 10.1128/aac.00863-24. Epub 2024 Aug 13.
3
Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria.在一项针对恶性疟原虫血液期疟疾的志愿者感染研究中对哌喹进行半机制药代动力学和药效学建模
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.01583-20.
4
Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.OZ439(artefenomel)对健康志愿者早期恶性疟原虫血液期疟疾感染的疗效。
J Antimicrob Chemother. 2016 Sep;71(9):2620-7. doi: 10.1093/jac/dkw174. Epub 2016 Jun 5.
5
Semi-mechanistic population pharmacokinetic/pharmacodynamic modeling of a elongation factor 2 inhibitor cabamiquine for prevention and cure of malaria.半机械论群体药代动力学/药效动力学模型,用于预防和治疗疟疾的延长因子 2 抑制剂卡巴喹。
Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0089123. doi: 10.1128/aac.00891-23. Epub 2023 Nov 15.
6
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.一项II期试点试验,旨在诱导性血液期疟疾感染研究中评估非诺喹对抗早期恶性疟原虫的安全性和有效性。
Malar J. 2016 Sep 13;15(1):469. doi: 10.1186/s12936-016-1511-3.
7
Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.在抗疟药物开发的转化路径中连接小鼠和人类恶性疟原虫攻击模型
Antimicrob Agents Chemother. 2016 May 23;60(6):3669-75. doi: 10.1128/AAC.02883-15. Print 2016 Jun.
8
Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.新型合成抗疟内过氧化物artefenomel(OZ439)治疗恶性疟原虫和间日疟原虫疟疾患者的抗疟活性:一项开放标签的2期试验
Lancet Infect Dis. 2016 Jan;16(1):61-69. doi: 10.1016/S1473-3099(15)00320-5. Epub 2015 Oct 5.
9
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.新型恶性疟原虫ATP4抑制剂SJ733的安全性、耐受性、药代动力学及抗疟疗效:一项人体首次诱导血期疟疾1a/b期试验
Lancet Infect Dis. 2020 Aug;20(8):964-975. doi: 10.1016/S1473-3099(19)30611-5. Epub 2020 Apr 8.
10
Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.基于机制的寄生虫生长模型和二氢青蒿素在鼠疟中的药效动力学。
Antimicrob Agents Chemother. 2013 Jan;57(1):508-16. doi: 10.1128/AAC.01463-12. Epub 2012 Nov 12.

引用本文的文献

1
Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment.2022 年基特森疟疾研讨会:从药物发现到治疗,对已取得的进展和未来的挑战进行了热烈讨论。
Trends Parasitol. 2022 Sep;38(9):711-718. doi: 10.1016/j.pt.2022.06.005. Epub 2022 Jul 18.
2
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.基于模型的抗感染药物研发:现状与未来。
Clin Pharmacol Ther. 2021 Apr;109(4):867-891. doi: 10.1002/cpt.2198. Epub 2021 Mar 9.

本文引用的文献

1
Comparison of statistical models to estimate parasite growth rate in the induced blood stage malaria model.诱导性血液期疟疾模型中估计寄生虫生长率的统计模型比较
Malar J. 2017 Aug 25;16(1):352. doi: 10.1186/s12936-017-1999-1.
2
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.用于研究多种疗法、多种疾病或两者兼有的主方案。
N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062.
3
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
新型长效抗疟药DSM265的安全性、耐受性、药代动力学及活性:一项分为两部分的首次人体1a/1b期随机研究
Lancet Infect Dis. 2017 Jun;17(6):626-635. doi: 10.1016/S1473-3099(17)30171-8. Epub 2017 Mar 28.
4
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.一项II期试点试验,旨在诱导性血液期疟疾感染研究中评估非诺喹对抗早期恶性疟原虫的安全性和有效性。
Malar J. 2016 Sep 13;15(1):469. doi: 10.1186/s12936-016-1511-3.
5
Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.OZ439(artefenomel)对健康志愿者早期恶性疟原虫血液期疟疾感染的疗效。
J Antimicrob Chemother. 2016 Sep;71(9):2620-7. doi: 10.1093/jac/dkw174. Epub 2016 Jun 5.
6
Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects.在健康受试者诱导性血液期疟疾研究中,对Actelion-451840抗疟作用的药代动力学/药效学建模。
Br J Clin Pharmacol. 2016 Aug;82(2):412-21. doi: 10.1111/bcp.12962. Epub 2016 May 11.
7
Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia.磷酸哌喹单药治疗药物敏感的恶性疟原虫感染可使疟原虫血症迅速清除,但随后会出现配子体血症。
J Infect Dis. 2016 Jul 1;214(1):105-13. doi: 10.1093/infdis/jiw128. Epub 2016 Apr 7.
8
Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.在抗疟药物开发的转化路径中连接小鼠和人类恶性疟原虫攻击模型
Antimicrob Agents Chemother. 2016 May 23;60(6):3669-75. doi: 10.1128/AAC.02883-15. Print 2016 Jun.
9
Efficiencies of platform clinical trials: A vision of the future.平台临床试验的效率:对未来的展望。
Clin Trials. 2016 Jun;13(3):358-66. doi: 10.1177/1740774515626362. Epub 2016 Feb 17.
10
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.首例人体安全性和药代动力学研究表明,合成臭氧化物 OZ439 的暴露概况优于其他过氧化物抗疟药。
Br J Clin Pharmacol. 2013 Feb;75(2):524-37. doi: 10.1111/j.1365-2125.2012.04368.x.